- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Success in Value-Based Contracting—Using Evidence, Technology, and Data to Improve Outcomes and Eliminate Low-Value Care, Part 3
Experts from Optum, WellMed, and Reliant discuss strategies for bringing value-based payment into specialty care through the use of education and analytics.
In the latest Matters in Managed Care webinar, experts discussed how to improve outcomes and eliminate low-value care. They defined actions and practices that constitute wasted and harmful care, described how to rapidly translate high-quality evidence-based medicine into daily practice, recognized how to leverage technology, and more.
Ken Cohen, MD, FACP, senior medical director and executive director, clinical research national senior medicaldirector, Optum Care, moderated the panel with:
- Troy Comstock, MD, regional medical director, Florida WellMed Medical Management
- Dan Murrey, MD, MPP, chief medical officer, surgical care associates; president, OptumCare Specialty Practices
- Thad Schilling, MD, chief medical officer, Reliant Medical Group
In segment 3, they discussed using analytics to control drug spend and optimize care.
Switching to Gene Therapy After Nusinersen or Risdiplam May Benefit Patients With SMA
August 15th 2025Children with spinal muscular atrophy (SMA) showed motor function improvements after switching to onasemnogene abeparvovec following prior treatment with nusinersen or risdiplam in a real-world study.
Read More
Blister Packs May Help Solve Medication Adherence Challenges and Lower Health Care Costs
June 10th 2025Julia Lucaci, PharmD, MS, of Becton, Dickinson and Company, discusses the benefits of blister packaging for chronic medications, advocating for payer incentives to boost medication adherence and improve health outcomes.
Listen
Taletrectinib Recommended in NCCN Guidelines for ROS1-Positive NSCLC
July 31st 2025Taletrectinib was added to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology as a preferred option for the first-line and subsequent treatment of advanced ROS1-positive non–small cell lung cancer (NSCLC).
Read More
